Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Bramstedt – page 11

1 461 clinical trials in Bad Bramstedt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Bramstedt at a glance
1 461
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 461 trials in Bad Bramstedt

Open in trial search

Phenylketonuria

Recruiting

A Phase 2 Study of MZE782 Safety, Tolerability, and Efficacy in Adults with Phenylketonuria

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MZE782
  • Sponsor:Maze Therapeutics Inc.

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy and Safety of Amara‑Tropfen Dilution vs Placebo in Patients with Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Artemisia absinthium, herba REC., ethanol. EXTR. 1:2,3
  • Sponsor:Weleda AG

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camoteskimab
  • Sponsor:Apollo Therapeutics Limited

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Bramstedt

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on systemic sclerosis treatment, investigating a novel subcutaneous therapy aimed at reducing skin sclerosis symptoms. These trials are evaluating new therapeutic approaches for managing this challenging autoimmune condition.

  • Skin sclerosis management
  • Subcutaneous administration methods
  • Novel therapeutic compounds

The research emphasizes improving treatment options for patients with progressive skin hardening and tissue fibrosis.

02 Rare Blood Disorders

Clinical investigations targeting Hypereosinophilic Syndrome, examining the effectiveness of new subcutaneous treatments for patients with uncontrolled disease states while maintaining standard care protocols.

  • Blood disorder management
  • Treatment resistance
  • Standard of care optimization

These studies aim to provide better therapeutic options for patients with rare eosinophilic conditions.

03 Inflammatory Conditions

Advanced research into systemic lupus erythematosus treatment, focusing on disease activity reduction and exploring new therapeutic compounds for this complex autoimmune disorder.

  • Disease activity assessment
  • Treatment safety evaluation
  • Long-term efficacy monitoring

The studies employ comprehensive assessment tools to measure treatment effectiveness in lupus patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.